Stroke and Fabry disease
详细信息 查看全文
- 作者：Miguel Viana-Baptista (12) mvianabaptista@fcm.unl.pt
- 关键词：Stroke – ; Fabry disease
- 刊名：Journal of Neurology
- 出版年：2012
- 出版时间：June 2012
- 年：2012
- 卷：259
- 期：6
- 页码：1019-1028
- 全文大小：339.0 KB
- 参考文献：1. Fellgiebel A, M眉ller MJ, Ginsberg L (2006) CNS manifestations of Fabry’s disease. Lancet Neurol 5:791–795
2. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ, International Collaborative Fabry Disease Study Group (2001) Safety and efficacy of recombinant human α-galactosidase. A replacement therapy in Fabry’s disease. N Engl J Med 345:9–16
3. Sims K, Politei J, Banikazemi M, Lee P (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry Registry. Stroke 40:788–794
4. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40
5. Rolfs A, B枚ttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, L枚hr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366:1794–1796
6. Brouns R, Sheorajpanday R, Braxel E, Eyskens F, Baker R, Hughes D, Mehta A, Timmerman T, Vincet MF, De Deyn PP (2007) Middleheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg 109:479–484
7. Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, Grace ME, Nazarenko I, Dobrovolny R, McDade E, Desnick RJ (2010) Frequency of unrecognized Fabry disease among young European–American and African–American men with first ischemic stroke. Stroke 41:78–81
8. Baptista MV, Ferreira S, Pinho-E-Melo T, Carvalho M, Cruz VT, Carmona C, Silva FA, Tuna A, Rodrigues M, Ferreira C, Pinto AA, Leit茫o A, Gabriel JP, Calado S, Oliveira JP, Ferro JM, PORTYSTROKE Investigators (2010) Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study—screening genetic conditions in Portuguese young stroke patients. Stroke 41:431–436
9. Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, Redondo P, Hemelsoet D, Fumal A, Jeangette S, Verslegers W, Baker R, Hughes D, De Deyn PP, BeFaS Investigators (2010) Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke 41:863–868
10. Rombach SM, Twickler TB, Aerts JMFG, Linthorst GE, Wijburg FA, Hollak CEM (2010) Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metabol 99:99–108
11. Desnick RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733–3774
12. Zarate YA, Hopkin RJ (2008) Fabry’s disease. Lancet 372:1427–1435
13. Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86–92
14. Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550–555
15. Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, Pashos CL (2002) Quality of life of patients with Fabry disease. Qual Life Res 11:317–327
16. Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, Aerts JM, Hollak CE (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68–78
17. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236–242
18. Schiffmann R (2009) Fabry disease. Pharmacol Ther 122:65–77
19. Moore Df, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, Charria-Ortiz G, Ferri R, Arai AE, Brady RO, Schiffmann R (2002) Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33:525–531
20. Grewal RP (1994) Stroke in Fabry’s disease. J Neurol 241:153–156
21. Fellgiebel A, Muller MJ, Mazanek M, Baron K, Beck M, Stoeter P (2005) White matter lesion severity in male and female patients with Fabry disease. Neurology 65:600–602
22. Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 3:924–932
23. Schiffmann R, Warnock D, Banikazemi M, Bultas J, Linthorst G, Packman S, Sorensen S, Wilcox W, Desnick R (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2102–2111
24. Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry’s disease. Ann Neurol 40:8–17
25. Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, Beck M, Ramaswani U, Linhart A, Gal A, Houge G, Widmer U, Mehta A, Sunder-plassman G (2006) Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 19:782–787
26. Jain G, Warnock DG (2011) Blood pressure, proteinuria and nephropathy in Fabry disease. Nephron Clin Pract 118:c43–c48
27. Crutchfield KE, Patronas NJ, Dambrosia JM, Frei KP, Benerjee TK, Barton NW, Schiffmann R et al (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50:1746–1749
28. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendel T, Marthol H (2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with fabry disease. J Neurol 251(5):564–570
29. Moore DF, Kaneski CR, Askari H, Schiffmann R (2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257:258–263
30. Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, Pease-Fye M, Ferri R, Brady RO, Herscovitch P, Schiffmann R (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104(13):1506–1512
31. Gupta S, Ries M, Kotsopoulos S, Schiffmann R (2005) The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine 84(5):261–268
32. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, Altarescu G, McCarron R, Schiffmann R (2000) Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47(2):229–233
33. Igarashi T, Sakuraba H, Suzuki Y (1986) Activation of platelet function in Fabry’s disease. Am J Hematol 22(1):63–67
34. Gambarin IF, Disabella E, Narula J, Diegoli M, Grasso M, Serio A, Favalli V, Agozzino M, Tavazzi L, Fraser AG, Arbustini E (2010) When should cardiologists suspect Anderson-Fabry disease. Am J Cardiol 106:1492–1499
35. Moon JC, Sachdev B, Elkington AG, Mc Kenna WJ, Metha A, Pennell DJ, Leed PJ, Elliot PM (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24:2151–2155
36. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR (2006) Fabry disease: guidelines for the evaluation and management of multiorgan system involvement. Genet Med 8:539–548
37. Politei JM (2009) Can we use statins to prevent stroke in Fabry disease? J Inherit Metab Dis 32:481–487
38. Demuth K, Germain DP (2002) Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr Suppl 91:57–61
39. Zenone T, Chan V ((2011) Young woman with recurrent ischemic strokes diagnosed as Fabry disease: lessons learned from a case report. Clin Neurol Neurosurg. doi:
40. Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A (2010) Effects of enzyme replacement therapy in Fabry disease—a comprehensive review of the medical literature. Genet Med 11:668–679
41. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345–354
42. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP, International Fabry Disease Study Group (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65–74
43. Jardim L, Vedolin L, Schwartz VD, Burin MG, Cecchin C, Kalakun L, Matte U, Aesse F, Pitta-Pinheiro C, Marconato J, Giugliani R (2004) CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 27:229–240
44. Yamadera M, Yokoe M, Beck G, Mihara M, Oe H, Yamamoto Y, Sakoda S (2009) Amelioration of white-matter lesions in a patient with Fabry disease. J Neurol Sci 279:118–120
45. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D (2011) American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 42(1):227–276
46. Cabrera-Salazar MA, O’Rourke E, Charria-Ortiz G, Barranger JA (2005) Radiological evidence of early cerebral microvascular disease in young children with Fabry disease. J Pediatr 147:102–105
47. Albrecht J, Dellani PR, M眉ller MJ, Schermuly I, Beck M, Stoeter P, Gerhard A, Fellgiebel A (2007) Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry 78:964–969
48. Moore DF, Altarescu G, BArker WC, Patronas NJ, Herscovitch P, Schiffmann R (2003) White matter lesions in Fabry disease occur in prior selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 62:231–240
49. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, Aerts JM, Hirth A, Hollak CE (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2:e598
50. Schermuly I, M眉ller MJ, M眉ller KM, Albrecht J, Keller I, Yakushev I, Beck M, Fellgiebel A (2011) Neuropsychiatric symptoms and brain structural alterations in Fabry disease. Eur J Neurol 18(2):347–353
51. Politei JM, Capizzano AA (2006) Magnetic resonance image findings in 5 young patients with Fabry disease. Neurologist 12(2):103–105
52. O’Sullivan M, Morris RG, Huckstep B, Jones DK, Williams SC, Markus HS (2004) Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis. J Neurol Neurosurg Psychiatry 75(3):441–447
53. Viana-Baptista M, Bugalho P, Jord茫o C, Ferreira N, Ferreira A, Forjaz Secca M, Esperan莽a-Pina JA, Ferro JM (2008) Cognitive function correlates with frontal white matter apparent diffusion coefficients in patients with leukoaraiosis. J Neurol 255(3):360–366
54. Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30
55. Fellgiebel A, Keller I, Marin D, M眉ller MJ, Schermuly I, Yakushev I, Albrecht J, Bellh盲user H, Kinateder M, Beck M, Stoeter P (2009) Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 72(1):63–68
56. Buechner S, Moretti M, Burlina AP, Cei G, Manara R, Ricci R, Mignani R, Parini R, Di Vito R, Giordano GP, Simonelli P, Siciliano G, Borsini W (2008) Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 79:1249–1254
57. Tedeschi G, Bonavita S, Banerjee TK, Virta A, Schiffmann R (1999) Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology 52:1663–1667
58. Marino S, Borsini W, Buchner S, Mortilla M, Stromillo ML, Battaglini M, Giorgio A, Bramanti P, Federico A, De Stefano N (2006) Diffuse structural and metabolic brain changes in Fabry disease. J Neurol 253(4):434–440
59. Ringelstein EB, Kleffner I, Dittrich R, Kuhlenb盲umer G, Ritter MA (2010) Hereditary and non-hereditary microangiopathies in the young. An up-date. J Neurol Sci 299(1–2):81–85
60. Fellgiebel A, Keller I, Martus P, Ropele S, Yakushev I, B枚ttcher T, Fazekas F, Rolfs A (2011) Basilar artery diameter is a potential screening tool for fabry disease in young stroke patients. Cerebrovasc Dis 31(3):294–299
61. Moore DF, Ye F, Schiffmann R, Butman JA (2003) Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. Am J Neuroradiol 24:1096–1101
62. Takanashi J, Barkovich AJ, Dillon WP, Sherr EH, Hart KA, Packman S (2003) T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. Am J Neuroradiol 24:916–921
63. Burlina AP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I, Burlina A, Lidove O (2008) The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol 255:738–744
64. Manara R, Ginsberg L, Severino S, Valentine AR, Kendall B, Clarke JTR, Mehta A, Burlina AP (2007) White matter and pulvinar signal abnormalities in Fabry disease: data from the Fabry Outcome Survey (FOS). J Neurol 254(Suppl 3):III/13
65. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE (2010) Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 47(4):217–222
66. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an underrecognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338–346
67. Gregoire SM, Brown MM, Collas DM, Jacob P, Lachmann RH, Werring DJ (2009) Posterior circulation strokes without systemic involvement as the presenting feature of Fabry disease. J Neurol Neurosurg Psychiatry 12:1414–1416
68. Rolfs A, Martus P, Heuschmann PU, Grittner U, Holzhausen M, Tatlisumak T, B枚ttcher T, Fazekas F, Enzinger C, Ropele S, Schmidt R, Riess O, Norrving B (2011) Protocol and methodology of the stroke in young Fabry patients (Sifap1) study: a prospective multicenter European study of 5,024 young stroke patients aged 18–55 years. Cerebrovasc Dis 31(3):253–262
69. Brouns R, Thijs V, De Eyskens F, Deyn PP (2011) Response to letter regarding Belgian Fabry study: Prevalence of Fabry disease in a cohort of 1,000 young patients with cerebrovascular disease. Stroke 42:e6–e7
70. Baumgartner R (2011) Prevalence of Fabry disease in ischemic stroke of unknown etiology. Available at: http://www.researchportal.ch/unizh/p8126.htm. Accessed June 2011
71. Clavelou P (2011) Fabry: National Initiative of Screening (FIND). Available at: http://clinicaltrials.gov/ct2/show/NCT00484549?term=fabry&rank=10. Accessed June 2011
72. Baptista MV, PORTYSTROKE investigators. 2011 Response to Letter Regarding Article, “Mutations of the GLA Gene in Young Patients With Stroke: The PORTYSTROKE Study-Screening Genetic Conditions in PORTuguese Young STROKE Patients”. Stroke; 42: e9
73. Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I (2003) Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 80:307–314
74. Chien YH (2009) Novel human pathological mutations: gene symbol: GLA disease: Fabry disease. Hum Genet 125:336
75. Wozniak MA, Kittner SJ, Cole JW, Stern B, Tuhrim S, Desnick RJ (2011) Response to letter regarding frequency of unrecognized Fabry disease among young European–American and African–American men with first ischemic stroke. Stroke 42: e8
76. Lidove O, Joly D, Touze’ E (2011) Letter regarding Brouns et al. Baptista et al. and Wozniak et al. Stroke 42:e4–e5
77. Carolei A, Marini C, Ferranti E, Frontoni M, Prencipe M, Fieschi C (1993) A prospective study of cerebral ischemia in the young. Analysis of pathogenic determinants. Stroke 24:362–367
78. Kristensen B, Malm J, Carlberg B, Stegmayr B, Backman C, Fagerlund M, Olsson T (1997) Epidemiology and etiology of stroke in young adults aged 18 to 44 years in northern Sweden. Stroke 28:1702–1709 - 作者单位：1. Departamento de Neurologia, CEDOC, Faculdade de Ci锚ncias M茅dicas, Universidade Nova de Lisboa, 1169-056 Lisbon, Portugal2. Servi莽o de Neurologia, Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, Rua da Junqueira 126, 1349-019 Lisbon, Portugal
- 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Neurology
Neurosciences
Neuroradiology - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-1459
文摘
Fabry disease (FD) is a rare inherited disorder of the metabolism, associated with renal, cardiac, and cerebrovascular complications. Ischemic and hemorrhagic stroke in FD present with a similar proportion to that observed in the general population, but usually at an early age. Ischemic stroke may result from cardiac embolism, large and small vessel disease, while hemorrhagic stroke is usually attributed to hypertension. Deposition of glycosphingolipids in endothelial cells results in a specific FD vasculopathy that contributes to the different vascular phenotypes. Neuroimaging features of cerebrovascular involvement in FD include white matter lesions, dolichoectasia, and the “pulvinar sign”, a T1 MRI hyperintensity of the posterior thalamus. The role of enzymatic replacement therapy in the prevention of stroke remains to be established, but its utilization should be considered in FD stroke patients, for prevention of renal and cardiac complications, together with general prevention measures. Enzymatic replacement therapy increased our awareness of FD, underlining the importance of incomplete phenotypes in specific settings such as stroke. An overview of studies on the prevalence of FD in stroke patients is presented. Available data suggest that prevalence of FD is similar to some of the rare causes of stroke usually considered, and that classic features of the disease may be absent or more subtle. Moreover, FD should be considered in both cryptogenic and all-cause stroke. The role of FD in stroke on a multifactorial basis and the identification of a putative “stroke variant” are questions that need to be further elucidated in future studies.